Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan
2009
Аутори
Mihailović-Stanojević, NevenaJovović, Đurđica
Miloradović, Zoran
Grujić-Milanović, Jelica
Jerkić, Mirjana
Marković-Lipkovski, Jasmina
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background. The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy. Methods. Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. Results. Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtratio...n rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. Conclusion. Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
Кључне речи:
adriamycin / losartan / renal disease progression / spontaneously hypertensive ratsИзвор:
Nephrology Dialysis Transplantation, 2009, 24, 4, 1142-1150Издавач:
- Oxford Univ Press, Oxford
Финансирање / пројекти:
- Улога биолошки активних молекула у експерименталним моделима кардиоваскуларних обољења (RS-145054)
- Имуноморфолошка карактеризација ћелија укључених у процес регенерације и фиброзе код обољења бубрега (RS-145034)
DOI: 10.1093/ndt/gfn596
ISSN: 0931-0509
PubMed: 18987260
WoS: 000264398800013
Scopus: 2-s2.0-65349132624
Институција/група
Institut za medicinska istraživanjaTY - JOUR AU - Mihailović-Stanojević, Nevena AU - Jovović, Đurđica AU - Miloradović, Zoran AU - Grujić-Milanović, Jelica AU - Jerkić, Mirjana AU - Marković-Lipkovski, Jasmina PY - 2009 UR - http://rimi.imi.bg.ac.rs/handle/123456789/216 AB - Background. The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy. Methods. Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. Results. Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. Conclusion. Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR. PB - Oxford Univ Press, Oxford T2 - Nephrology Dialysis Transplantation T1 - Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan EP - 1150 IS - 4 SP - 1142 VL - 24 DO - 10.1093/ndt/gfn596 ER -
@article{ author = "Mihailović-Stanojević, Nevena and Jovović, Đurđica and Miloradović, Zoran and Grujić-Milanović, Jelica and Jerkić, Mirjana and Marković-Lipkovski, Jasmina", year = "2009", abstract = "Background. The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy. Methods. Six-month-old female SHR were randomly selected in six groups. Two control groups (SH(6), SH(12)) received vehicle. Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w. i.v.) twice in a 3-week interval. Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR. Animals were killed after 6 or 12 weeks, respectively. Haemodynamic measurements were performed on anaesthetized animals, blood and urine samples were taken for biochemical analysis and the left kidney was processed for morphological studies. Results. Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. Conclusion. Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.", publisher = "Oxford Univ Press, Oxford", journal = "Nephrology Dialysis Transplantation", title = "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan", pages = "1150-1142", number = "4", volume = "24", doi = "10.1093/ndt/gfn596" }
Mihailović-Stanojević, N., Jovović, Đ., Miloradović, Z., Grujić-Milanović, J., Jerkić, M.,& Marković-Lipkovski, J.. (2009). Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. in Nephrology Dialysis Transplantation Oxford Univ Press, Oxford., 24(4), 1142-1150. https://doi.org/10.1093/ndt/gfn596
Mihailović-Stanojević N, Jovović Đ, Miloradović Z, Grujić-Milanović J, Jerkić M, Marković-Lipkovski J. Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. in Nephrology Dialysis Transplantation. 2009;24(4):1142-1150. doi:10.1093/ndt/gfn596 .
Mihailović-Stanojević, Nevena, Jovović, Đurđica, Miloradović, Zoran, Grujić-Milanović, Jelica, Jerkić, Mirjana, Marković-Lipkovski, Jasmina, "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan" in Nephrology Dialysis Transplantation, 24, no. 4 (2009):1142-1150, https://doi.org/10.1093/ndt/gfn596 . .